• Arpiprazole as adjunctive therapy to metformin significantly reduced HbA1c by 0.8% compared to placebo in T2DM patients.
• Fasting plasma glucose and triglyceride levels improved significantly with arpiprazole treatment.
• The safety profile of arpiprazole was comparable to placebo, with no serious adverse events reported.
• Arpiprazole may offer a novel therapeutic option for glycemic control in non-insulin-dependent T2DM.